Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/DYRK1A_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/DYRK1A_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/DYRK1A_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/DYRK1A_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DYRK1A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/DYRK1A_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DYRK1A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/DYRK1A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DYRK1A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DYRK1A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00182105 | Lung | IAC | peptidyl-threonine modification | 33/2061 | 125/18723 | 1.22e-06 | 6.43e-05 | 33 |
GO:00106398 | Lung | IAC | negative regulation of organelle organization | 68/2061 | 348/18723 | 1.69e-06 | 8.24e-05 | 68 |
GO:19029038 | Lung | IAC | regulation of supramolecular fiber organization | 73/2061 | 383/18723 | 1.87e-06 | 8.87e-05 | 73 |
GO:00181075 | Lung | IAC | peptidyl-threonine phosphorylation | 31/2061 | 116/18723 | 1.92e-06 | 8.98e-05 | 31 |
GO:00331198 | Lung | IAC | negative regulation of RNA splicing | 12/2061 | 25/18723 | 4.03e-06 | 1.66e-04 | 12 |
GO:00514947 | Lung | IAC | negative regulation of cytoskeleton organization | 38/2061 | 163/18723 | 5.35e-06 | 2.08e-04 | 38 |
GO:00003817 | Lung | IAC | regulation of alternative mRNA splicing, via spliceosome | 19/2061 | 60/18723 | 1.36e-05 | 4.05e-04 | 19 |
GO:00003807 | Lung | IAC | alternative mRNA splicing, via spliceosome | 22/2061 | 77/18723 | 1.85e-05 | 5.22e-04 | 22 |
GO:19029047 | Lung | IAC | negative regulation of supramolecular fiber organization | 37/2061 | 167/18723 | 2.38e-05 | 6.50e-04 | 37 |
GO:00435163 | Lung | IAC | regulation of DNA damage response, signal transduction by p53 class mediator | 13/2061 | 34/18723 | 3.34e-05 | 8.32e-04 | 13 |
GO:00512588 | Lung | IAC | protein polymerization | 56/2061 | 297/18723 | 3.90e-05 | 9.51e-04 | 56 |
GO:00083808 | Lung | IAC | RNA splicing | 75/2061 | 434/18723 | 4.89e-05 | 1.12e-03 | 75 |
GO:20010207 | Lung | IAC | regulation of response to DNA damage stimulus | 44/2061 | 219/18723 | 5.50e-05 | 1.22e-03 | 44 |
GO:00064762 | Lung | IAC | protein deacetylation | 25/2061 | 101/18723 | 7.38e-05 | 1.55e-03 | 25 |
GO:19033128 | Lung | IAC | negative regulation of mRNA metabolic process | 22/2061 | 92/18723 | 3.30e-04 | 5.19e-03 | 22 |
GO:2001021 | Lung | IAC | negative regulation of response to DNA damage stimulus | 20/2061 | 81/18723 | 3.87e-04 | 5.89e-03 | 20 |
GO:00331206 | Lung | IAC | positive regulation of RNA splicing | 12/2061 | 37/18723 | 4.06e-04 | 6.14e-03 | 12 |
GO:00356012 | Lung | IAC | protein deacylation | 25/2061 | 112/18723 | 4.18e-04 | 6.25e-03 | 25 |
GO:00987322 | Lung | IAC | macromolecule deacylation | 25/2061 | 116/18723 | 7.26e-04 | 9.60e-03 | 25 |
GO:00322718 | Lung | IAC | regulation of protein polymerization | 42/2061 | 233/18723 | 8.87e-04 | 1.11e-02 | 42 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DYRK1A | SNV | Missense_Mutation | | c.217G>C | p.Asp73His | p.D73H | Q13627 | protein_coding | deleterious(0) | benign(0.364) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DYRK1A | SNV | Missense_Mutation | | c.1744C>G | p.His582Asp | p.H582D | Q13627 | protein_coding | tolerated_low_confidence(0.18) | possibly_damaging(0.84) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DYRK1A | SNV | Missense_Mutation | | c.1976N>T | p.Ser659Phe | p.S659F | Q13627 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.962) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DYRK1A | SNV | Missense_Mutation | | c.1626C>A | p.Phe542Leu | p.F542L | Q13627 | protein_coding | tolerated(0.05) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DYRK1A | SNV | Missense_Mutation | | c.161N>T | p.Ser54Phe | p.S54F | Q13627 | protein_coding | deleterious_low_confidence(0.01) | benign(0.044) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
DYRK1A | SNV | Missense_Mutation | | c.46C>T | p.Arg16Trp | p.R16W | Q13627 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.454) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
DYRK1A | SNV | Missense_Mutation | | c.492G>C | p.Leu164Phe | p.L164F | Q13627 | protein_coding | deleterious(0.02) | probably_damaging(0.949) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
DYRK1A | SNV | Missense_Mutation | | c.2230N>C | p.Asp744His | p.D744H | Q13627 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.99) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
DYRK1A | SNV | Missense_Mutation | | c.183G>C | p.Gln61His | p.Q61H | Q13627 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.626) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
DYRK1A | SNV | Missense_Mutation | | c.1898A>G | p.Tyr633Cys | p.Y633C | Q13627 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.984) | TCGA-E2-A15E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme1WO2011135259 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme15-1 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme6Pyrrolo[2,3-d]pyrimidines | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme23MPPDerivatives | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | inhibitor | 249565842 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme13INDY | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | inhibitor | 405560505 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme4Upper | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme12-3 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme18 | | |